Tag:

Merck

Latest Headlines

Latest Headlines

Japan's PeptiDream, Merck in targeted peptide deal

Japan's PeptiDream said it and Merck signed a collaboration agreement to produce targeted peptides for treating a variety of diseases. The arrangement is the latest in the biopharmaceutical's long list of deals with multinational drug makers.

Biotech's boom spells a spike in R&D down payments

The average upfront value in biotech deals hit a 9-year peak in 2014, according to Morrison & Foerster, part of a virtuous cycle in life sciences that has pushed asset valuations ever upward.

As California measles cases mounted, so did Merck measles vaccine sales

The California measles outbreak may have just given new meaning to the phrase "scaring up some business." As news of the outbreak spread, health officials urged parents to vaccinate their children. And as more and more cases were reported--escalating from 7 cases to more than 100 in just one month--sales of Merck's M-M-R II vaccine shot up too,

Merck could be in for big Januvia boost, thanks to 'completely balanced' heart data

In one quick announcement Monday, Merck's diabetes drug Januvia became the drug to beat in its class. New study data could boost Januvia's sales by 10% in 2020.

Time for an asthma check, doc? AstraZeneca-sponsored EHR reminders will tell you

Physicians who use Practice Fusion for their electronic health records know the software alerts them when certain patients need check-ups or shots. Now, there's a new alert in town, especially for asthma and COPD sufferers--but this one is funded by AstraZeneca.

FDA bats down Merck's sugammadex in third rejection

Merck execs used their quarterly review today to confirm that the troubled drug Bridion (sugammadex) has once again been rejected at the FDA. This is the drug's third stiff arm at the agency.

Flush with Q1 success, Merck touts coming launches in hep C, lung cancer

Merck & Co. had a lot to brag about with first-quarter earnings. Sales and profits beat analyst forecasts. It's preparing to launch its new cancer med in a big new market. And it ticked off a triad of study victories that could give its product line a boost.

Merck and Gilead square off in battle of the next-next-gen hep C combos

Early today both Gilead and Merck issued new data on their next-next-gen hepatitis C combos, demonstrating just how brutal the competition for market share is becoming while highlighting some of the boundaries that are emerging in shortening treatment regimens.

Deep discounts allow Remicade biosimilar to grab 50% of Norway's market

Conventional thinking is that the complexity of biosimilars will keep their discounts to just 20% to 30% of the branded price. Think again. In Norway a biosimilar of Merck's arthritis blockbuster Remicade is going for a discount of nearly 70%, upsetting conventional wisdom and competitors.

Merck aims for double payoff with new diabetes education push

With Januvia contributing billions in critical revenue, Merck has backed its fair share of diabetes education and awareness efforts. But with its latest, the company may give vaccine sales a boost, too.